Compare RSSS & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RSSS | MNOV |
|---|---|---|
| Founded | 2006 | 2000 |
| Country | United States | United States |
| Employees | N/A | 6 |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 86.5M | 69.4M |
| IPO Year | 2008 | 2004 |
| Metric | RSSS | MNOV |
|---|---|---|
| Price | $2.57 | $1.47 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $5.00 | ★ $7.50 |
| AVG Volume (30 Days) | ★ 45.2K | 21.8K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 130.77 | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $28,793,922.00 | $2,360,807.00 |
| Revenue This Year | $1.81 | N/A |
| Revenue Next Year | $5.73 | $180.00 |
| P/E Ratio | $64.25 | ★ N/A |
| Revenue Growth | 2.77 | ★ 194.15 |
| 52 Week Low | $2.15 | $1.17 |
| 52 Week High | $4.12 | $1.96 |
| Indicator | RSSS | MNOV |
|---|---|---|
| Relative Strength Index (RSI) | 54.11 | 59.25 |
| Support Level | $2.48 | $1.40 |
| Resistance Level | $2.60 | $1.54 |
| Average True Range (ATR) | 0.11 | 0.04 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 41.43 | 76.47 |
Research Solutions Inc is a holding company. The company provides vertical software-as-a-service ("SaaS") and artificial intelligence ("AI") solutions, providing software and related services to help research-intensive organizations simplify the research process, save time, and money. The company operates in a single segment, which derives its revenue from subscription fees from its cloud-based SaaS Platforms and transactional service fees for the electronic delivery of single articles. The company generates the majority of its revenue from the Transactions. Geographically, the company generates the majority of its revenue from the United States, followed by Europe.
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.